Rytelo (imetelstat) / Geron 
Welcome,         Profile    Billing    Logout  
 144 Diseases   5 Trials   5 Trials   837 News 


«12345678»
  • ||||||||||  Review, Journal:  Current and emerging strategies for management of myelodysplastic syndromes. (Pubmed Central) -  Sep 5, 2021   
    Targeted therapies approved for acute myeloid leukemia treatment, such as isocitrate dehdyrogenase inhibitors and venetoclax, are also being studied for use in MDS. In this review, we provide a brief overview of pathogenesis and current treatment strategies in MDS followed by a discussion of newer agents that are under clinical investigation.
  • ||||||||||  imetelstat (JNJ-63935937) / Geron
    Check out imetelstat (Twitter) -  Aug 8, 2021   
  • ||||||||||  imetelstat (JNJ-63935937) / Geron
    Imetelstat (Twitter) -  Aug 6, 2021   
  • ||||||||||  imetelstat (JNJ-63935937) / Geron
    Imetelstat (Twitter) -  Aug 6, 2021   
  • ||||||||||  imetelstat (JNJ-63935937) / Geron
    Biomarker, Journal:  Targeting Telomere Biology in Acute Lymphoblastic Leukemia. (Pubmed Central) -  Jul 21, 2021   
    TL and TA might complement established markers for the identification of patients with high-risk ALL. Moreover, TA seems to be an effective therapeutic target; hence, telomerase inhibitors, such as imetelstat, may augment standard ALL treatment.
  • ||||||||||  Review, Journal:  Novel therapeutics in myeloproliferative neoplasms. (Pubmed Central) -  Jun 8, 2021   
    Despite improving biological understanding of these complex clonal hematopoietic stem/progenitor cell neoplasms, none of the currently available therapies appear to modify the proclivity of the disease per se, thereby remaining an urgent unmet clinical need and an ongoing area of intense clinical investigation. This review will highlight the evolving targeted therapeutic agents that are in early- and late-stage MPN clinical development.
  • ||||||||||  imetelstat (JNJ-63935937) / Geron
    Clinical, Journal:  Developing strategies to reduce the duration of therapy for patients with myeloproliferative neoplasms. (Pubmed Central) -  Jun 5, 2021   
    The experimental drug Imetelstat is a promising drug that has been reported to prolong survival in very high risk myelofobrosis patients after a limited period of time of administration. New experimental drugs and drug combinations that target the malignant clone and/or microenviromental abnormalities have the potential to eliminate MRD, which might allow for drug holidays and reduction in the duration of therapy.
  • ||||||||||  imetelstat (JNJ-63935937) / Geron, Jakafi oral (ruxolitinib) / Novartis, Incyte
    Journal, Combination therapy:  Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new era. (Pubmed Central) -  Jun 5, 2021   
    A discussion of recent clinical trials on interferon and ruxolitinib in ET and PV patients is provided followed by an outline of the future challenges in the field particularly for novel therapeutics and an increasingly individualized, molecularly driven approach to treatment selection...While hydroxyurea remains the first-line treatment for cytoreduction in most high-risk ET and PV patients, the disease-modifying potential of IFN is promising and could make it a preferred option for selected patients. Advances in molecular testing will enable a more individualized approach to prognostication and treatment selection.
  • ||||||||||  [VIRTUAL] Potential New Therapeutic Approaches for Myelofibrosis () -  May 20, 2021 - Abstract #SOHO2021SOHO_158;    
    Targeting the p53-HDM2 Axis KRT-232 is a first-in-class, potent, bioavailable inhibitor of HDM2 (key negative regulator of p53) that was assessed in a phase 2 study (KRT-232-101) and showed promising clinical efficacy and tolerability in TP53-wild type patients with MF who failed ruxolitinib treatment.17 A randomized phase 3 trial comparing KRT-232 (240 mg on days 1–7/28-day cycle) to BAT in MF patients refractory /resistant to JAK inhibitors has been launched...In the phase 2 study IMbark, the higher dose of imetelstat (9.4 mg/ kg) yielded a median overall survival of 29.9 months in patients with intermediate-2 or high-risk MF relapsed/refractory to JAK inhibitors.18 In light of the aforementioned promising result, a pivotal international phase 3 trial (IMpactMF) was launched to evaluate the survival advantage – an unprecedented trial endpoint for investigational MF medications – that imetelstat may confer to JAK-inhibitor-refractory MF patients.19 Conclusions The era of JAK1/2 inhibitor monotherapies in MF has ushered the way to the clinical development of a suite of promising novel medications spanning various biological mechanisms (for example, inhibitors of BET, HDM2, BCL-2/ BCL-XL, and telomerase, among others). Several highly promising candidates are currently evaluated in regulatory phase 3 clinical trials in the frontline and second line settings; these studies may lead to approval of novel medications that will significantly improve the current MF treatment paradigm.
  • ||||||||||  imetelstat (JNJ-63935937) / Geron, Revlimid (lenalidomide) / BMS, Zarzio (filgrastim biosimilar) / Novartis
    [VIRTUAL] IMETELSTAT DEMONSTRATES AN ACCEPTABLE SAFETY PROFILE IN MYELOID MALIGNANCIES () -  May 13, 2021 - Abstract #EHA2021EHA_1864;    
    Methods These safety analyses focus on MYF2001 study pts randomized to imetelsat 9.4 mg/kg IV q 3 weeks (wks) (N=59) as of 7 Feb 2020 and the Phase 2 of the MDS3001 study in LR/Int-1 non-del(5q) transfusion dependent ESA R/R MDS pts, all lenalidomide and hypomethylating agent-naïve (N=38), who received 7.5 mg/kg IV every 4 wks as of 21 Oct 2020...Differences in disease pathology (proliferation vs dysplasia) could account for the differences in toxicity profiles in MF vs MDS pts. Ongoing Phase 3 studies in MF and MDS will confirm the safety profile of imetelstat in a controlled setting.
  • ||||||||||  imetelstat (JNJ-63935937) / Geron, BIBR1532 / Boehringer Ingelheim
    Review, Journal:  Telomerase: key regulator of inflammation and cancer. (Pubmed Central) -  Mar 30, 2021   
    Despite significant effort invested in developing telomerase-targeted therapeutics, devising efficacious cancer-specific telomerase/TERT inhibitors remains an uphill task. The latest discoveries of the telomere-independent functionalities of telomerase in inflammation and cancer can help illuminate the path of developing specific anti-telomerase/TERT therapeutics against cancer cells.
  • ||||||||||  imetelstat (JNJ-63935937) / Geron
    Clinical, Journal, IO biomarker:  Myelosuppression in Patients Treated with the Telomerase Inhibitor Imetelstat Is Not Mediated through Activation of Toll-Like Receptors. (Pubmed Central) -  Mar 12, 2021   
    Furthermore, imetelstat treatment of the MPN cell line HEL did not impact the expression of TLR signaling pathway target genes that are commonly induced by activation of different TLRs, whereas it significantly reduced its target gene hTERT, human telomerase reverse transcriptase, in a dose- and time-dependent manner. Hence, cytopenias, especially thrombocytopenia observed in some patients treated with imetelstat, are not mediated by off-target interactions with TLRs.
  • ||||||||||  Journal:  Investigational non-JAK inhibitors for chronic phase myelofibrosis. (Pubmed Central) -  Jan 21, 2021   
    Drugs that target new molecular pathways (MDM2, p-selectin, TIM-3, Bcl-2, TGF-β, aurora kinase) and immune-based strategies (CALR vaccine, anti-PD-1, allogeneic cord blood regulatory T cells) are in early phase trials. Further translational studies to target leukemic stem cells, improvement in trial designs by incorporating control arm and survival endpoints, and patient-focused collaborations among all stakeholders could pave a way for future success in MF drug development.
  • ||||||||||  Clinical, Review, Journal, IO biomarker:  Telomerase-based cancer therapeutics: a review on their clinical trials. (Pubmed Central) -  Jan 1, 2021   
    Many of these therapeutic tools are under different stages of clinical trials and have shown promising outcomes. In this review, we highlight the current status of telomerase-based cancer therapeutics and the outcome of these investigations.